3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
9
Stomach Neoplasms
6
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Solid Tumor
3
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Muscle Invasive Bladder Cancer
1
Interventions
Irinotecan
3
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
palbociclib
1
encorafenib
1
Pemetrexed
1
Levoleucovorin
1
Leucovorin
1
KRN-330
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Gemcitabine
1
Flucytosine
1
Everolimus
1
Cisplatin
1
Cetuximab
1
Capecitabine
1
Ascorbic Acid
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Digestive System Neoplasms
×
tislelizumab
×
Clear all
NCT06022692
2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2
Completed
18 enrolled